Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Entera Bio Ltd ENTX

Entera Bio Ltd., a clinical stage company, focuses on developing oral peptide or protein replacement therapies for unmet medical needs. The company leverages its N-Tab platform that is designed to simultaneously stabilize the peptide in the gastrointestinal tract and promote its absorption into the bloodstream. It also develops EB613, an oral PTH (1-34), that has completed Phase 2 clinical... see more

Current News (NDAQ:ENTX)

Entera Bio Congratulates the FNIH-ASBMR-SABRE Team on FDA's Qualification of Total Hip BMD as Regulatory Endpoint: Huge Win for Osteoporosis Innovation

GlobeNewswire December 23, 2025

Entera Bio Announces New Data Supporting Further Development of a Proprietary First-in-Class Oral, Long-Acting PTH Tablet for Patients with Hypoparathyroidism (EB612 Program)

GlobeNewswire December 22, 2025

Entera Bio to Participate in the 8th Annual Evercore ISI Healthcare Conference

GlobeNewswire November 18, 2025

Entera Bio Announces Third Quarter 2025 Financial Results and Business Updates

GlobeNewswire November 14, 2025

Entera Bio Presents Positive New Clinical Data from EB613 Phase 2 Trial Demonstrating Significant Bone Density Improvements in Early Postmenopausal Women

GlobeNewswire October 23, 2025

Entera Bio to Present New Clinical Data from Phase 2 Trial of EB613 at the 2025 North American Menopause Society (NAMS) Annual Meeting

GlobeNewswire October 16, 2025

Entera Bio Reports Positive PK Data for First-in-Class Oral GLP-2 Tablet Treatment for Patients with Short Bowel Syndrome at the 2025 ESPEN Congress

GlobeNewswire September 15, 2025

Entera Bio Presents Positive Effects of EB613 on Both Trabecular and Cortical Bone in Postmenopausal Women with Osteoporosis at ASBMR 2025

GlobeNewswire September 8, 2025

Entera Bio to Unveil Clinical and Non-Clinical Data Across 3 Oral Peptide Programs at Upcoming September Conferences

GlobeNewswire August 28, 2025

Opinion & Analysis (NDAQ:ENTX)

No current opinion is available.

Bullboard Posts (NDAQ:ENTX)

Using technical analysis for this stock.

It is starting a big uptrend from this point forward today so good luck to all
coolfooldumbguy - July 28, 2025

ENTERA BIO: A GAME CHANGER IN OSTEOPOROSIS IN THE OFFING!

$ENTX ENTERA BIO: A GAME CHANGER IN OSTEOPOROSIS IN THE OFFING!   https://www.aviseanalytics.com/entera-bio-a-game-changer-in...
AviseAnalytics - June 25, 2021

ENTX ... have to go

c u tomorrow. Cheers !
Iseneschal - June 23, 2021

ENTX ....volume por favor !!!!

rtyrth
Iseneschal - June 23, 2021

ENTX ....maybe another run ?

.oudhge
Iseneschal - June 23, 2021

ENTX ....did that....now breaking DTL

Let's see what happens
Iseneschal - June 23, 2021

Podcasts